Not checked for notices yet.

Tolerogenic bone marrow-derived dendritic cells induce neuroprotective regulatory T cells in a model of Parkinson’s disease

Charles R. Schutt, Howard E. Gendelman, R. Lee Mosley

Molecular Neurodegeneration · 2018

doi:10.1186/s13024-018-0255-7

References 77

1.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
2.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
3.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
4.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
5.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
6.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
7.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
8.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
9.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
10.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
11.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
12.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
13.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
14.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
15.
CD4+ Regulatory and Effector/Memory T Cell Subsets Profile Motor Dysfunction in Parkinson’s Disease · 2012
No notice
16.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
17.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
18.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
19.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
20.
Nitrated α–Synuclein Immunity Accelerates Degeneration of Nigral Dopaminergic Neurons · 2008
No notice
21.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
22.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
23.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
24.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
25.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
26.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
27.
Adaptive Immune Neuroprotection in G93A-SOD1 Amyotrophic Lateral Sclerosis Mice · 2008
No notice
28.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
29.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
30.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
31.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
32.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
33.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
34.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
35.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
36.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
37.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
38.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
39.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
40.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
41.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
42.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
43.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
44.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
45.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
46.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
47.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
48.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
49.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
50.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
51.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
52.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
53.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
54.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
55.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
56.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
57.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
58.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
59.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
60.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
61.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
62.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
63.
Comparative study of clinical grade human tolerogenic dendritic cells · 2011
No notice
64.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
65.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
66.
Increased epigenetic age and granulocyte counts in the blood of Parkinson's disease patients · 2015
No notice
67.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
68.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
69.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
70.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
71.
Neuroprotective effects of CD4+CD25+Foxp3+ regulatory T cells in a 3xTg-AD Alzheimer's disease model · 2016
No notice
72.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
73.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
74.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
75.
Evaluation of the safety and immunomodulatory effects of sargramostim in a randomized, double-blind phase 1 clinical Parkinson’s disease trial · 2017
No notice
76.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
77.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library

Cited by papers we hold 3

Aging and Neurodegenerative Disease: Is the Adaptive Immune System a Friend or Foe? · 2020
No notice
Harnessing regulatory T cell neuroprotective activities for treatment of neurodegenerative disorders · 2020
No notice
Roles of GM-CSF in the Pathogenesis of Autoimmune Diseases: An Update · 2019
No notice

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.